Vaccine Technology
The experimental vaccine uses mRNA technology similar to COVID-19 vaccines but encodes proteins from multiple respiratory viruses. Researchers combined antigens from influenza A and B strains, respiratory syncytial virus, and four seasonal coronaviruses. The approach aims to provide broad protection with single administration.
Clinical Trial Results
Phase 2 trials involving 3,000 adults showed 75 percent efficacy in preventing symptomatic infection from targeted viruses. Protection lasted at least 12 months with minimal side effects. Most participants experienced only mild injection site reactions and low-grade fever lasting 1-2 days.
Public Health Implications
If approved, the vaccine could simplify seasonal vaccination schedules and improve coverage rates. Health authorities note potential to reduce winter hospitalizations from respiratory illnesses. Manufacturers plan to seek regulatory approval in 2027 pending successful Phase 3 results.